Mar 28 |
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
|
Mar 14 |
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
|
Mar 5 |
Purple Biotech GAAP EPADS of -$0.19
|
Mar 5 |
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
|
Feb 27 |
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
|
Feb 13 |
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
|
Feb 1 |
Purple Biotech stock climbs 9% on Phase 2 study update
|
Feb 1 |
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
|
Dec 20 |
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
|
Dec 14 |
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
|